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Background: Vancomycin is the primary treatment for infections caused by methicilin-resistant Staphylococcus
aureus (MRSA). The association of vancomycin treatment failures with increased vancomycin minimum inhibitory
concentration (MIC) is a well-recognized problem. A number of single-centre studies have identified progressive
increases in glycopeptide MICs for S. aureus strains over recent years – a phenomenon known as vancomycin MIC
creep. It is unknown if this is a worldwide phenomenon or if it is localized to specific centers.
Methods: The aim of this study was to evaluate the trend of vancomycin MIC for isolates of MRSA over a 3-year
period in a tertiary university hospital in Portugal. MRSA isolates from samples of patients admitted from January
2007 to December 2009 were assessed. Etest method was used to determine the respective vancomycin MIC. Only
one isolate per patient was included in the final analysis.
Results: A total of 93 MRSA isolates were studied. The vancomycin MICs were 0.75, 1, 1.5 and 2 mg/L for 1 (1.1%),
19 (20.4%), 38 (40.9%), 35 (37.6%) isolates, respectively. During the 3 year period, we observed a significant
fluctuation in the rate of MRSA with a vancomycin MIC > 1 mg/L (2007: 86.2%; 2008: 93.3%; 2009: 58.8%, p = 0.002).
No MRSA isolate presented a MIC > 2 mg/L.
Conclusions: We were unable to find in our institution data compatible to the presence of vancomycin MIC creep
during the study period. This phenomenon seems not to be generalized; as a result each institution should
systematically monitor MRSA vancomycin MIC over time.Background
According to the Surveillance Network database, which
collected laboratory data from 300 clinical microbiology
laboratories across the United States, from 1998 to
March 2005 with more than 3 million bacterial isolates,
Staphylococcus aureus was the most prevalent (18.7%)
species isolated from inpatient specimens and the sec-
ond most prevalent (14.7%) species from outpatient
specimens [1]. In 2005, MRSA rates were 59.2%, 55%,
and 47.9% for strains from non-intensive care unit (ICU)
inpatients, ICU, and outpatients, respectively [1].* Correspondence: joanapsilvestre@gmail.com
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reproduction in any medium, provided the orAlthough the proportion of Staphylococcus aureus
bacteraemia due to MRSA is declining in many coun-
tries, data from the European Antimicrobial Resistance
Surveillance System (EARSS) for 2010 showed that in
more than one-third of countries the proportion
remained >25% [2]. The highest rates were reported
from the Mediterranean countries, with Portugal being
the only country showing MRSA rates above 50% [2,3].
The Portuguese data were further confirmed by Melo-
Cristino et al. in a recent study [4].
Vancomycin, a glycopeptide antimicrobial, was initially
used to treat infections with penicillin-resistant Staphylo-
coccus aureus before alternative, less-toxic drugs were
introduced [5]. Subsequently this glycopeptide became
vital for the treatment of infections with MRSA [5].
Vancomycin is now the 1st line treatment for infections
caused by MRSA [6]. However, vancomycin treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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susceptible to vancomycin.
There are a number of types of susceptibility test
available. Traditionally, agar disk diffusion has been
used to measure glycopeptide susceptibility, but now
this method is not regarded as standard, since it does
not measure the MIC. This method is not suitable for
large antibiotic molecules, such as glycopeptides and
daptomycin, because they diffuse too slowly into agar.
An alternative method for measuring glycopeptide MIC
is broth microdilution – the gold-standard test for
measuring antibiotic MICs. Automated susceptibility
testing systems are also widely used, but the perform-
ance of this methodology for measuring glycopeptide
MICs has been frequently questioned. Etest has been
developed as an accurate and easier agar plate method.
An Etest strip, which contains a gradient of antibiotic,
is placed on an inoculated agar plate and the pattern of
bacterial growth is examined after 24 hours. Since the
Etest uses a gradient of antibiotic concentration, it has
greater precision than disc diffusion methods, allowing
better ascertainment of the actual MIC.
There is a growing body of evidence showing a
sustained increase in the MICs of glycopeptides against
Staphylococcus aureus strains, a process referred to as
“MIC creep”, however with several conflicting results
[7-9].
Thus, the primary objective of our study was to evalu-
ate MIC trends for clinical MRSA isolates to vanco-
mycin over a 3-year period in one hospital using the
Etest.
Methods
This study was previously approved by the ethical com-
mittee of our institution; no informed consent was
needed, according to the ethical principles of the declar-
ation of Helsinki.
Microorganisms
Clinical MRSA isolates from cultures were collected
from sequential individual patients at São Francisco
Xavier Hospital, Lisbon, from January 2007 to December
2009. São Francisco Xavier Hospital is a central and uni-
versity hospital of Lisbon, which belongs to a 900 beds
Hospital Centre serving a population of about 935,000
people as a tertiary referral center.
The MRSA isolates were collected mainly from blood-
stream, from respiratory tract (tracheal aspirate and
bronchoalveolar lavage) and from synovial fluid.
Only one isolate per patient was included in this
analysis. For those patients with more than one iso-
late, only the first isolate was tested. All isolates were
identified as Staphylococcus aureus according to
standard methods.Antibiotics evaluated
MICs of vancomycin and oxacillin were determined by
the Etest. Oxacillin testing was performed to confirm
oxacillin resistance.
MIC testing methods
For each isolate prior to MIC testing, a single bead
was aseptically removed from the Microbank vial and
spread onto the surface of trypticase soy agar plates
supplemented with 5% sheep blood. These plates were
then incubated overnight (18 – 24 h) at 35°C in ambi-
ent air. Each isolate was subcultured and incubated
overnight for a second time under the same conditions.
From these plates, portions of three to five individual
colonies were inoculated into 5 mL of physiologic
serum and incubated for 18 h. A 0.5 McFarland turbid-
ity standard was used to streak the inoculums onto the
surface of a 150 mm Mueller – Hinton II agar plate.
The surface of the plate was allowed to dry for 15 min
prior to Etest strip application.
The MIC testing was performed using the Etest
method, following manufacturer’s guidelines. The anti-
biotic Etest strips were applied to the agar surface using
an Etest applicator and were not moved following appli-
cation. The MICs were read in 24-48 h. The MIC testing
of the organisms was performed over a period of 4 weeks
in a single laboratory.
The susceptibility breakpoint was 2 mg/L for vanco-
mycin. The breakpoint for oxacillin resistance was
4 mg/L. Actual Etest MIC values were used for all
calculations and analyses and not rounded up to the next
highest traditional 2-fold MIC value.
Statistical analysis
Standard descriptive statistics were used. Continuous
variables were reported as mean ± standard deviation.
Continuous variables were analyzed using the paramet-
ric unpaired Student’s t test, the nonparametric Mann–
Whitney U test or Kruskal-Wallis H test, according to
data distribution. Categorical variables were compared
using the Chi-square test.
MIC trends over the 3 years were assessed using non-
parametric methods. For the analysis of MIC trends over
time, Chi-square test was used.
Tests were performed two-tailed and considered signifi-
cant when p < 0.05. All statistical tests were performed
using SPSS for Windows (version 16.0: SPSS, Chicago,
IL, USA) [4].
Results
During the study period a total of 93 MRSA isolates
from 93 patients were collected for analysis. Twenty-
nine isolates (31,2%) were recovered in 2007, 30 (32,3%)
in 2008 and 34 (36,6%) during 2009.
Table 1 Clinical and demographic characteristics from the
methicilin-resistant Staphylococcus aureus (N = 93)
N = 93
Age, mean (± SD) 76,7 ± 13,0
Gender, F (%) 52 (55,9%)
Department, N (%)
Emergency department 44 (47,3%)
Medical ward 27 (29,0%)
Intensive care unit 18 (19,3%)
Surgical ward 4 (4,3%)
MRSA, N (%)
Blood cultures 53 (57%)
Respiratory tract 39 (41,9%)
Others 1 (1,1%)
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from bloodstream and from respiratory tract (41,9%)
mainly from tracheal aspirate. Only one MRSA was
collected from synovial fluid. Clinical and demographic
characteristics are presented in Table 1.
The lowest MIC was 0.75 mg/L that was observed in
only one isolate.
Nineteen isolates (20.4%) had MIC 1 mg/L, 38 (40,9%)
isolates had MIC 1.5 mg/L and 35 (37.6%) had MIC
2 mg/L. No MRSA isolate presented a MIC >2 mg/L.
The MIC distribution for vancomycin is displayed in
Figure 1. During the 3 year study period, we observed
a significant fluctuation in the rate of MRSA with a
vancomycin MIC > 1 mg/L (2007: 86.2%, 2008: 93.3%,
2009: 58.8%). Overall MICs for vancomycin declined
during the study period. The MIC trends appeared to
either plateau or slightly increase between 2007 and
2008, (p = n.s) but decreased in 2009 (p = 0.002).
Discussion
Methicillin-resistant Staphylococcus aureus is a major









Figure 1 Vancomycin MIC population distribution 2007 – 09.associated with high mortality rates and healthcare costs
[10,11].
Studies reporting vancomycin MIC creep with MRSA
have produced conflicting results. Minimum inhibitory
concentration creep over time has been noted in some
studies but large multicentre surveillance studies have not
reported the same type of findings over time [12-14].
The factors involved in the development of reduced sus-
ceptibility to vancomycin and subsequent “glycopeptide
MIC creep” are not entirely elucidated, but recognition of
the phenomenon is important since it may be a precur-
sor to hVISA and VISA [15]. This phenomenon, MIC
creep, is of clinical concern because poorer treatment
outcomes have been associated with higher vancomycin
MICs [9,16-20].
Some authors advocate that combining data from mul-
tiple centers can obscure trends that may exist in one in-
stitution [14]. Some of these studies utilize less-sensitive
traditional susceptibility markers (e.g. percentages,
MIC50, MIC90) in their analyses. Vancomycin MIC re-
sult also varies by method of testing with Etest results
tending to be 0.5–1.5 log2 dilutions higher than
reference broth method [21-23]. On the other hand,
combining data from multiple centers can obscure
trends that may exist within a given institution or coun-
try as a result of differences in patient populations and
drug usage patterns.
In our institution we were unable to find data compat-
ible with the presence of vancomycin MIC creep among
MRSA over a 3-year period, on the contrary we found a
significant statistical decline in vancomycin MIC creep
in 2009.
Our study had some limitations. First, this is a retro-
spective single center study, possibly introducing a selec-
tion bias. Second, the number of patients enrolled was
small, making statistical calculations problematic. Third,
MICs were only analyzed over a 3-year period, longer
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this study we analyzed only one isolate per patient and
only isolates in significative samples were included
(colonizations were not analyzed).
Conclusions
In conclusion, though the cause of vancomycin “MIC
creep” is unknown, decreased MRSA susceptibility to
vancomycin is likely due to overuse as well as to sub-
optimal vancomycin dosing. The phenomenon known as
MIC creep has been observed only in the last 20 years.
Critical evaluation of site of infection, MIC data, aggres-
sive dosing with close monitoring and follow up is
warranted with vancomycin therapy. We also advise that
all hospitals should monitor their local status of vanco-
mycin MICs in invasive MRSA isolates to screen for the
possibility of MIC creep.
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